Johnson & Johnson reports one-year FUZION results for TREMFYA in Crohn's disease
The company said TREMFYA maintained combined fistula remission through 48 weeks in adults with Crohn's disease and perianal fistula, with 35% remission at Week 48 in the 100 mg q8w group. More than 90% of all randomized patients completed treatment through Week 48, and safety findings were consistent with the established safety profile.
Primary source
Company press release (PR Newswire), October 19, 2026
Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula
Machine-summarized from the source above; not independently reported. How we use automation